Next week should be a big week for IPIX. I am expe
Post# of 72444
(Total Views: 1027)
Posted On: 07/05/2020 3:50:16 PM
Next week should be a big week for IPIX. I am expecting an update from the company. The Trump administration is expected to announce its new Covid19 program with more emphasis on therapuetics such as Brilacidin. IMO they have come to the realization the vaccines are going to take a long time and they need encouraging Covid 19 treatment news before the election. My hope we have a good treatment before the election and Brilacidin is part of the answer.
Looking forward IPIX has many reasons to be optimistic. The last company update showed Brilacidin for OM is ready to enter a stage 3 FDA trial. Oral Brilacidin for Ulcerative Colitis has shown effective targeting of the colon and plans are being made for a stage 2 trial. Kevetrin demonstrated activation of p53 in its stage 2 trial.
http://www.ipharminc.com/new-blog/2020/6/25/u...-june-2020
Brilacidin for RBL studies using human pulmonary and renal cells confirmed it is effective in vitro against Covid19 (p<0.0001) and plans are being made to study its effects against MERS,Sars Viral encephalitis and other viruses.
In addition the RBL labs are moving forward to publish 2 peer review articles about Brilacidin's successful Coronavirus tests.
The RBL was so impressed it will assist Brilacidin's grant application: "testing results observed to date formed the basis for a federal grant application that was submitted last week by the RBL, in collaboration with the Company, proposing to evaluate Brilacidin’s potential as a pan-coronavirus therapeutic, with possible extension into other viruses"
http://www.ipharminc.com/press-release/2020/6...-cell-line
http://www.ipharminc.com/press-release/2020/6...herapeutic
It is important to remember the RBL labs are under Dr Fauci's NIAID. If any other therapeutic has had this level of independent testing and success against Covid 19 I am unaware of it being reported.
The next steps will be more funding, government grants, clinical trials.
We will see IPIX expand by hiring additional employees to manage the trials.
The stock price should increase with each step. I expect IPIX will be uplisted to a better exchange. After the clinical trials we should have a good idea of IPIX's value and at that stage I believe we will be looking at partners and /or licensing opportunities for Brilacidin for Covid 19, ulcerative Colitis and Oral mucositis.
Later IPIX should have funds to complete the Oral Kevetrin drug and begin clinical trials for Ovarian cancer and Acute Myelogenous Leukemia.
This time next year IPIX will be a very different company.
JMO GLTA Farrell
Looking forward IPIX has many reasons to be optimistic. The last company update showed Brilacidin for OM is ready to enter a stage 3 FDA trial. Oral Brilacidin for Ulcerative Colitis has shown effective targeting of the colon and plans are being made for a stage 2 trial. Kevetrin demonstrated activation of p53 in its stage 2 trial.
http://www.ipharminc.com/new-blog/2020/6/25/u...-june-2020
Brilacidin for RBL studies using human pulmonary and renal cells confirmed it is effective in vitro against Covid19 (p<0.0001) and plans are being made to study its effects against MERS,Sars Viral encephalitis and other viruses.
In addition the RBL labs are moving forward to publish 2 peer review articles about Brilacidin's successful Coronavirus tests.
The RBL was so impressed it will assist Brilacidin's grant application: "testing results observed to date formed the basis for a federal grant application that was submitted last week by the RBL, in collaboration with the Company, proposing to evaluate Brilacidin’s potential as a pan-coronavirus therapeutic, with possible extension into other viruses"
http://www.ipharminc.com/press-release/2020/6...-cell-line
http://www.ipharminc.com/press-release/2020/6...herapeutic
It is important to remember the RBL labs are under Dr Fauci's NIAID. If any other therapeutic has had this level of independent testing and success against Covid 19 I am unaware of it being reported.
The next steps will be more funding, government grants, clinical trials.
We will see IPIX expand by hiring additional employees to manage the trials.
The stock price should increase with each step. I expect IPIX will be uplisted to a better exchange. After the clinical trials we should have a good idea of IPIX's value and at that stage I believe we will be looking at partners and /or licensing opportunities for Brilacidin for Covid 19, ulcerative Colitis and Oral mucositis.
Later IPIX should have funds to complete the Oral Kevetrin drug and begin clinical trials for Ovarian cancer and Acute Myelogenous Leukemia.
This time next year IPIX will be a very different company.
JMO GLTA Farrell
(15)
(1)